PLPL - Plandaí Biotechnology, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0052
0.0000 (0.00%)
As of 1:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0052
Open0.0059
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0052 - 0.0059
52 Week Range0.0041 - 0.0300
Volume626,198
Avg. Volume2,409,555
Market Cap969,961
Beta-2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Plandai Biotechnology Provides Comment on SEC Action

    Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.

  • GlobeNewswire2 months ago

    Plandaí Biotechnology Announces Successful Completion of Government Inspection of Affiliate Protext Pharma’s Proposed Medical Cannabis Facility

    Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly bioavailable extracts, today announced that its affiliate company, Protext Pharma, Inc. (TXTM), held a meeting July 4th 2018 at the company’s office in White River, Mpumalanga, with senior Government staff members of the South African Health Products Regulatory Authority (SAHPRA) (formerly known as the Medicine Control Council-MCC). The meetings included in-depth discussion of the company’s anticipated medical cannabis business in the country, site visit and complete inspection of a large industrial building the company has secured and plans to use for growing, cultivating and extraction of cannabis for medical research and development purposes.  The completion of the facility site inspection is a big milestone in the process of pursuing this government issued license, and is believed to be the final hurdle before Protext and one of its subsidiaries is issued one of the first licenses in South Africa that will allow for establishing a research and development platform for developing cannabis based medicines.

  • GlobeNewswire3 months ago

    Plandai Biotechnology Exploring Opportunities in the U.S. Poultry Market

    The United States has the largest broiler chicken industry in the world with about 16.5 percent of production exported to other countries in 2017. In 2017, almost 9 billion broiler chickens, weighing over 55 billion pounds liveweight, were produced.